Health Care · Pharmaceutical Preparations · Nasdaq · CIK 886163 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $288.01Day −2.79%Mkt cap $5.8BP/E (FY) 47.0×1Y +118.9%Off 52W high −11.8%Vol (1Y) 37.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.6% of sh out |
| Days to cover5.0d |
| 13F net flow (QoQ)+0.34% |
| Top-10 13F concentration47.3% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)47.0× |
| Sales (TTM)$274.5M |
| Earnings (TTM)$153.6M |
| ROE13.5% |
| Net margin46.4% |
| ROIC7.5% |
| Sales growth 3Y11.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+52.3% |
| 1Y+118.9% |
| 3Y+330.3% |
| 5Y+288.1% |
| 10Y+242.3% |
| Since incept. (ann.)+13.1% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)37.0% |
| Ann. volatility (3Y)39.6% |
| Sharpe (1Y)2.26 |
| Sharpe (3Y)1.42 |
| Max drawdown (1Y)−14.1% |
| Max drawdown (3Y)−29.9% |
| Beta (3Y vs SPY)1.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 3.0M | $591M | 14.78% | +0.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.1M | $220M | 5.49% | new |
| JANUS HENDERSON GROUP PLC | 1.0M | $202M | 5.04% | +1.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 848,089 | $169M | 4.23% | new |
| Invesco Ltd. | 823,604 | $164M | 4.11% | +59.5% |
| STATE STREET CORP | 778,856 | $155M | 3.89% | +3.7% |
| FMR LLC | 596,127 | $119M | 2.97% | +2.9% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573,312 | $114M | 2.86% | −11.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 1,455,087 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.67 | — | $51.7M | +14.1% |
| 2025-12-31 | 2026-02-26 | — | — | $59.7M | +39.4% |
| 2025-09-30 | 2025-11-06 | $5.68 | — | $115.5M | +122.8% |
| 2025-06-30 | 2025-08-07 | $0.24 | — | $47.6M | +14.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Development And Licensing Of Biopharmaceutical Assets 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
